Alkermes Pharma Ireland Limited
7 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
22
Ending by 2030
Jun 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 3 fees due Nov 19 to 28, 2026 · next Nov 19
- 2 fees due Dec 11 to 20, 2026 · next Dec 11
- 5 fees due Jan 7 to 28, 2027 · next Jan 7
- 3 fees due Feb 8 to 18, 2027 · next Feb 8
- 6 fees due Mar 1 to 15, 2027 · next Mar 1
- 2 fees due Apr 1 to 24, 2027 · next Apr 1
- 2 fees due May 19 to 24, 2027 · next May 19
- 1 fee due Jun 15, 2027The maintenance fee for Opioid Agonist Antagonist Combinations (US 9,211,293) comes due Jun 15, 2027. Unpaid by Dec 15, 2027, it lapses early.
- 1 fee due Jul 30, 2027The maintenance fee for Crystallization Process of Aripiprazole Derivatives in Extended Release Formulations for Treatment of Schizophrenia (US 11,883,394) comes due Jul 30, 2027. Unpaid by Jan 31, 2028, it lapses early.
- 1 fee due Aug 20, 2027The maintenance fee for Prodrugs of Fumarates and Their Use in Treating Various Diseases (US 11,905,298) comes due Aug 20, 2027. Unpaid by Feb 22, 2028, it lapses early.
- 3 fees due Sep 10 to 24, 2027 · next Sep 10
- 2 fees due Oct 9 to 30, 2027 · next Oct 9
- 1 fee due Nov 5, 2027The maintenance fee for Pharmaceutical Compositions Having Improved Storage Stability (US 10,639,376) comes due Nov 5, 2027. Unpaid by May 5, 2028, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 21, 2026
- Oct 27 US 12,773,396 Prodrugs of Fumarates and Their Use in Treating Various Diseases
- Sep 29 US 12,746,237 Crystallization Process of Aripiprazole Derivatives in Extended Release Formulations for Treatment of Schizophrenia
- 1 term has ended since Aug 21, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,842,232 | Sterilization of Dispersions of Nanoparticulate Active Agents with Gamma Radiation In force · High confidence | In force | High confidence | |
| US 8,293,871 | Poly(LACTIDE-CO-GLYCOLIDE) Based Sustained Release Microcapsules Comprising a Polypeptide and a Sugar In force · Low confidence | In force | Low confidence | |
| US 7,910,577 | Injectable Nanoparticulate Olanzapine Formulations In force · High confidence | In force | High confidence | |
| US 7,919,499 | Naltrexone Long Acting Formulations and Methods of Use In force · High confidence | In force | High confidence | |
| US 9,345,665 | Reduction of Flake-Like Aggregation in Nanoparticulate Active Agent Compositions In force · Medium confidence | In force | Medium confidence | |
| US 9,974,746 | Reduction of Flake-Like Aggregation in Nanoparticulate Active Agent Compositions In force · Medium confidence | In force | Medium confidence | |
| US 9,974,747 | Reduction of Flake-Like Aggregation in Nanoparticulate Active Agent Compositions In force · Low confidence | In force | Low confidence | |
| US 9,974,748 | Reduction of Flake-Like Aggregation in Nanoparticulate Active Agent Compositions In force · Low confidence | In force | Low confidence | |
| US 11,253,478 | Reduction of Flake-Like Aggregation in Nanoparticulate Active Agent Compositions In force · Medium confidence | In force | Medium confidence | |
| US 11,717,481 | Reduction of Flake-Like Aggregation in Nanoparticulate Active Agent Compositions In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 120: 7 patents in force now held by others · 46 lapsed for an unpaid fee · 170 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 74 abandoned · 6 no status recorded